Bifogade filer
Ziccum AR 2023
Kurs
-6,05%
Likviditet
0,13 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2025-01-29 | 08:30 | Bokslutskommuniké 2024 |
| 2024-11-08 | - | Extra Bolagsstämma 2024 |
| 2024-10-29 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-30 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-28 | - | Årsstämma |
| 2024-05-17 | - | X-dag ordinarie utdelning ZICC 0.00 SEK |
| 2024-04-29 | - | Kvartalsrapport 2024-Q1 |
| 2024-01-26 | - | Bokslutskommuniké 2023 |
| 2023-10-25 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-18 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-21 | - | X-dag ordinarie utdelning ZICC 0.00 SEK |
| 2023-06-20 | - | Årsstämma |
| 2023-04-26 | - | Kvartalsrapport 2023-Q1 |
| 2023-01-27 | - | Bokslutskommuniké 2022 |
| 2022-10-27 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-23 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-29 | - | X-dag ordinarie utdelning ZICC 0.00 SEK |
| 2022-04-28 | - | Årsstämma |
| 2022-04-28 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2022-01-18 | - | Extra Bolagsstämma 2022 |
| 2021-10-28 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-04-28 | - | X-dag ordinarie utdelning ZICC 0.00 SEK |
| 2021-04-27 | - | Årsstämma |
| 2021-04-23 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-11 | - | Bokslutskommuniké 2020 |
| 2020-11-06 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-20 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-17 | - | X-dag ordinarie utdelning ZICC 0.00 SEK |
| 2020-06-16 | - | Årsstämma |
| 2020-04-17 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-13 | - | Bokslutskommuniké 2019 |
| 2019-11-07 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-21 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-20 | - | Årsstämma |
| 2019-05-10 | - | X-dag ordinarie utdelning ZICC 0.00 SEK |
| 2019-05-09 | - | Kvartalsrapport 2019-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Ziccum today announces that its Annual Report for 2023 is now available on the company’s website www.ziccum.com.
To read the Report in full (in Swedish) please visit here: https://ziccum.com/investors/financial-reports/
For more information about Ziccum, please contact:
Ann Gidner,
CEO Ziccum
Mail: gidner@ziccum.com
Mobile: +46 722140141
Fredrik Sjövall,
Chairman of the Board, Ziccum AB
Mail: sjovall@ziccum.com
Mobile: +46 706 45 08 75
Ziccum’s Certified Adviser is
Carnegie Investment Bank AB (publ).
Follow us on https://eucaps.com/ziccum
About Ziccum
Ziccum is developing LaminarPaceTM, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPaceTM uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application. Ziccum is listed on the Nasdaq First North Growth Market.